ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-18

Study Completion Date

2022-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Hepatocellular Carcinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ATEZOLIZUMAB, BEVACIZUMAB , Advanced hepatocellular carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment
* Child Pugh A and ECOG 0 or 1
* upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated
* non eligible to receive a locoregional therpay or progressive after this kinf of treatment
* with informed consent

Exclusion Criteria

* refuse to participate
* under legal protection

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre-Guillaume Poureau, MD

Role: CONTACT

Phone: 0298223740

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

29BRC20.0325

Identifier Type: -

Identifier Source: org_study_id